Want to see SE:ISOFOL full AI Analyst Report?
ISOFOL Stock Chart & Stats
kr0.72
-kr0.10(-6.34%)
At close: 4:00 PM EST
kr0.72
-kr0.10(-6.34%)
Day’s Range― - ―
52-Week Rangekr0.55 - kr1.08
Previous CloseN/A
Volume134.77K
Average Volume (3M)501.89K
Market Cap
kr233.96M
Enterprise Valuekr71.98
Total Cash (Recent Filing)kr110.74M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.03
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding320,491,640
10 Day Avg. Volume847,726
30 Day Avg. Volume501,890
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageIsofol's near-zero debt materially reduces financing risk for a clinical-stage biotech, giving management more flexibility to fund trials or negotiate partnerships without immediate debt servicing pressure. This structural balance-sheet strength supports continuity over the next several months.
Improving Cash BurnA marked reduction in free cash outflow to roughly -3.6M TTM signals improving operational control and a smaller near-term financing requirement. For a drug developer, this improvement extends runway and reduces dilution pressure, a durable benefit over a 2–6 month horizon.
Focused Clinical-Stage PipelineIsofol's concentrated strategy around arfolitixorin, a proprietary candidate for use with 5‑FU in colorectal cancer, provides clear clinical and commercial focus. A single prioritized asset streamlines resource allocation and makes regulatory progress or partnership outcomes materially impactful long-term.
Bears Say
No Revenue BaseThe absence of ongoing revenue means Isofol cannot self-fund operations and remains fully dependent on external capital or deals. Over months this structural lack of commercial cash flow increases financing risk and limits internal reinvestment capacity for trials and development.
Material Equity ErosionA large decline in shareholder equity over recent years reflects cumulative losses and capital consumption. This erosion reduces the balance-sheet cushion, heightens the probability of future dilution or asset sales, and materially constrains strategic optionality across the 2–6 month horizon.
Persistent Negative Operating Cash FlowConsistently negative operating cash flow (~-55.6M TTM) indicates the business model does not generate internal funding and depends on financing cycles. This structural cash burn makes long-term trial execution and regulatory timelines contingent on successful capital raises or partnerships.
Isofol Medical AB News
ISOFOL FAQ
What was Isofol Medical AB’s price range in the past 12 months?
Isofol Medical AB lowest stock price was kr0.55 and its highest was kr1.08 in the past 12 months.
What is Isofol Medical AB’s market cap?
Isofol Medical AB’s market cap is kr233.96M.
When is Isofol Medical AB’s upcoming earnings report date?
Isofol Medical AB’s upcoming earnings report date is Aug 25, 2026 which is in 36 days.
How were Isofol Medical AB’s earnings last quarter?
Isofol Medical AB released its earnings results on May 19, 2026. The company reported -kr0.054 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Isofol Medical AB overvalued?
According to Wall Street analysts Isofol Medical AB’s price is currently Overvalued.
Does Isofol Medical AB pay dividends?
Isofol Medical AB does not currently pay dividends.
What is Isofol Medical AB’s EPS estimate?
Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Isofol Medical AB have?
Isofol Medical AB has 320,491,640 shares outstanding.
What happened to Isofol Medical AB’s price movement after its last earnings report?
Isofol Medical AB reported an EPS of -kr0.054 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.636%.
Which hedge fund is a major shareholder of Isofol Medical AB?
Currently, no hedge funds are holding shares in SE:ISOFOL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Isofol Medical AB
Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is presently undergoing Phase 3 clinical trials for individuals with advanced colorectal cancer. The company has forged significant strategic alliances with organizations including Recipharm, Merck & Cie, and Sahlgrenska University Hospital. Established in 2008, its corporate base is situated in Gothenburg, Sweden.
Technical Analysis
Xintela AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Bio-Works Technologies AB
―